Shire Outlines Baxalta Integration Strategy

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

First quarter financial results brought another growth period for Shire PLC, but perhaps the most noteworthy information provided by the company on its April 29 earnings call, was its strategy for integrating Baxalta Inc. into its infrastructure, assuming both companies' boards approve the transaction when they meet separately on May 27.

Overall, the Dublin-headquartered specialty firm reported product sales of $1.627bn for the first quarter of 2016, up 14% year-over-year. As usual, the top-seller was attention-deficit/hyperactivity disorder (ADHD) stalwart Vyvanse (lisdexamfetamine), which posted 22% growth to $509m on the quarter. It also was a strong quarter for Shire's hereditary angioedema franchise, as Firazyr (icatibant) sales increased 39% to $128m and Cinryze (C1 esterase inhibitor) sales rose 11% to $164m.

Initially launched as a hostile bid in mid-2015, Shire's acquisition of Baxalta was agreed upon in January at a price...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

Test Roche Head Of Pharma Strategy Karsten Jung On Rebuilding The Portfolio

 
• By Jessica Merrill

The Swiss pharma company is rebalancing the portfolio, emphasizing best-in-class drugs and moving into new areas like cardiovascular and metabolic disease.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Reed Miller

In this week's episode: Trump’s UK drug pricing win; Novo explains semaglutide Alzheimer's rationale; J&J and Novartis on this year’s biggest M&A deals; a look at the mixed performance of CAR-Ts; and Akeso’s goals beyond ivonescimab.

Article Without An Author Listed

Here is a short description.

Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]

Pipelines in bioconjugates continue to develop, from ADCs to XDCs, with radionuclide drug conjugates (RDCs) and antibody-oligonucleotide conjugates (AOCs) leading the expansion.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains